NS-089/NCNP-02

About Nippon Shinyaku

Nippon Shinyaku's mission is to address high-unmet medical needs through pioneering science, particularly in rare diseases. Its key achievement is the development and commercialization of Viltepso (viltolarsen), an exon-skipping therapy for Duchenne muscular dystrophy, establishing its technological credibility. The company's strategy is built on deep R&D in targeted therapeutic areas, a dominant position in the Japanese market, and strategic international expansion, especially in the United States.

Therapeutic Areas